298 related articles for article (PubMed ID: 28348404)
1. Proteogenomic integration reveals therapeutic targets in breast cancer xenografts.
Huang KL; Li S; Mertins P; Cao S; Gunawardena HP; Ruggles KV; Mani DR; Clauser KR; Tanioka M; Usary J; Kavuri SM; Xie L; Yoon C; Qiao JW; Wrobel J; Wyczalkowski MA; Erdmann-Gilmore P; Snider JE; Hoog J; Singh P; Niu B; Guo Z; Sun SQ; Sanati S; Kawaler E; Wang X; Scott A; Ye K; McLellan MD; Wendl MC; Malovannaya A; Held JM; Gillette MA; Fenyö D; Kinsinger CR; Mesri M; Rodriguez H; Davies SR; Perou CM; Ma C; Reid Townsend R; Chen X; Carr SA; Ellis MJ; Ding L
Nat Commun; 2017 Mar; 8():14864. PubMed ID: 28348404
[TBL] [Abstract][Full Text] [Related]
2. Proteogenomic Landscape of Breast Cancer Tumorigenesis and Targeted Therapy.
Krug K; Jaehnig EJ; Satpathy S; Blumenberg L; Karpova A; Anurag M; Miles G; Mertins P; Geffen Y; Tang LC; Heiman DI; Cao S; Maruvka YE; Lei JT; Huang C; Kothadia RB; Colaprico A; Birger C; Wang J; Dou Y; Wen B; Shi Z; Liao Y; Wiznerowicz M; Wyczalkowski MA; Chen XS; Kennedy JJ; Paulovich AG; Thiagarajan M; Kinsinger CR; Hiltke T; Boja ES; Mesri M; Robles AI; Rodriguez H; Westbrook TF; Ding L; Getz G; Clauser KR; Fenyö D; Ruggles KV; Zhang B; Mani DR; Carr SA; Ellis MJ; Gillette MA;
Cell; 2020 Nov; 183(5):1436-1456.e31. PubMed ID: 33212010
[TBL] [Abstract][Full Text] [Related]
3. Targeting mTOR pathway inhibits tumor growth in different molecular subtypes of triple-negative breast cancers.
Hatem R; El Botty R; Chateau-Joubert S; Servely JL; Labiod D; de Plater L; Assayag F; Coussy F; Callens C; Vacher S; Reyal F; Cosulich S; Diéras V; Bièche I; Marangoni E
Oncotarget; 2016 Jul; 7(30):48206-48219. PubMed ID: 27374081
[TBL] [Abstract][Full Text] [Related]
4. Proteogenomics connects somatic mutations to signalling in breast cancer.
Mertins P; Mani DR; Ruggles KV; Gillette MA; Clauser KR; Wang P; Wang X; Qiao JW; Cao S; Petralia F; Kawaler E; Mundt F; Krug K; Tu Z; Lei JT; Gatza ML; Wilkerson M; Perou CM; Yellapantula V; Huang KL; Lin C; McLellan MD; Yan P; Davies SR; Townsend RR; Skates SJ; Wang J; Zhang B; Kinsinger CR; Mesri M; Rodriguez H; Ding L; Paulovich AG; Fenyö D; Ellis MJ; Carr SA;
Nature; 2016 Jun; 534(7605):55-62. PubMed ID: 27251275
[TBL] [Abstract][Full Text] [Related]
5. Characterization and validation of potential therapeutic targets based on the molecular signature of patient-derived xenografts in gastric cancer.
Chen Z; Huang W; Tian T; Zang W; Wang J; Liu Z; Li Z; Lai Y; Jiang Z; Gao J; Shen L
J Hematol Oncol; 2018 Feb; 11(1):20. PubMed ID: 29433585
[TBL] [Abstract][Full Text] [Related]
6. Proteome-wide onco-proteogenomic somatic variant identification in ER-positive breast cancer.
Dimitrakopoulos L; Prassas I; Sieuwerts AM; Diamandis EP; Martens JWM; Charames GS
Clin Biochem; 2019 Apr; 66():63-75. PubMed ID: 30684468
[TBL] [Abstract][Full Text] [Related]
7. Mass Spectrometry-Based Proteogenomics: New Therapeutic Opportunities for Precision Medicine.
Joshi SK; Piehowski P; Liu T; Gosline SJC; McDermott JE; Druker BJ; Traer E; Tyner JW; Agarwal A; Tognon CE; Rodland KD
Annu Rev Pharmacol Toxicol; 2024 Jan; 64():455-479. PubMed ID: 37738504
[TBL] [Abstract][Full Text] [Related]
8. A large collection of integrated genomically characterized patient-derived xenografts highlighting the heterogeneity of triple-negative breast cancer.
Coussy F; de Koning L; Lavigne M; Bernard V; Ouine B; Boulai A; El Botty R; Dahmani A; Montaudon E; Assayag F; Morisset L; Huguet L; Sourd L; Painsec P; Callens C; Chateau-Joubert S; Servely JL; Larcher T; Reyes C; Girard E; Pierron G; Laurent C; Vacher S; Baulande S; Melaabi S; Vincent-Salomon A; Gentien D; Dieras V; Bieche I; Marangoni E
Int J Cancer; 2019 Oct; 145(7):1902-1912. PubMed ID: 30859564
[TBL] [Abstract][Full Text] [Related]
9. Integrative Proteo-genomic Analysis to Construct CNA-protein Regulatory Map in Breast and Ovarian Tumors.
Ma W; Chen LS; Özbek U; Han SW; Lin C; Paulovich AG; Zhong H; Wang P
Mol Cell Proteomics; 2019 Aug; 18(8 suppl 1):S66-S81. PubMed ID: 31281117
[TBL] [Abstract][Full Text] [Related]
10. Proteogenomic Analysis of Breast Cancer Transcriptomic and Proteomic Data, Using De Novo Transcript Assembly: Genome-Wide Identification of Novel Peptides and Clinical Implications.
Hari PS; Balakrishnan L; Kotyada C; Everad John A; Tiwary S; Shah N; Sirdeshmukh R
Mol Cell Proteomics; 2022 Apr; 21(4):100220. PubMed ID: 35227895
[TBL] [Abstract][Full Text] [Related]
11. Computational identification of micro-structural variations and their proteogenomic consequences in cancer.
Lin YY; Gawronski A; Hach F; Li S; Numanagic I; Sarrafi I; Mishra S; McPherson A; Collins CC; Radovich M; Tang H; Sahinalp SC
Bioinformatics; 2018 May; 34(10):1672-1681. PubMed ID: 29267878
[TBL] [Abstract][Full Text] [Related]
12. Preclinical Efficacy of Ron Kinase Inhibitors Alone and in Combination with PI3K Inhibitors for Treatment of sfRon-Expressing Breast Cancer Patient-Derived Xenografts.
Bieniasz M; Radhakrishnan P; Faham N; De La O JP; Welm AL
Clin Cancer Res; 2015 Dec; 21(24):5588-600. PubMed ID: 26289070
[TBL] [Abstract][Full Text] [Related]
13. Functional proteogenomics reveals biomarkers and therapeutic targets in lymphomas.
Rolland DCM; Basrur V; Jeon YK; McNeil-Schwalm C; Fermin D; Conlon KP; Zhou Y; Ng SY; Tsou CC; Brown NA; Thomas DG; Bailey NG; Omenn GS; Nesvizhskii AI; Root DE; Weinstock DM; Faryabi RB; Lim MS; Elenitoba-Johnson KSJ
Proc Natl Acad Sci U S A; 2017 Jun; 114(25):6581-6586. PubMed ID: 28607076
[TBL] [Abstract][Full Text] [Related]
14. Proteogenomic studies on cancer drug resistance: towards biomarker discovery and target identification.
Fu S; Liu X; Luo M; Xie K; Nice EC; Zhang H; Huang C
Expert Rev Proteomics; 2017 Apr; 14(4):351-362. PubMed ID: 28276747
[TBL] [Abstract][Full Text] [Related]
15. Current status of clinical proteogenomics in lung cancer.
Nishimura T; Nakamura H; Végvári Á; Marko-Varga G; Furuya N; Saji H
Expert Rev Proteomics; 2019 Sep; 16(9):761-772. PubMed ID: 31402712
[No Abstract] [Full Text] [Related]
16. Integrated molecular pathway analysis informs a synergistic combination therapy targeting PTEN/PI3K and EGFR pathways for basal-like breast cancer.
She QB; Gruvberger-Saal SK; Maurer M; Chen Y; Jumppanen M; Su T; Dendy M; Lau YK; Memeo L; Horlings HM; van de Vijver MJ; Isola J; Hibshoosh H; Rosen N; Parsons R; Saal LH
BMC Cancer; 2016 Aug; 16():587. PubMed ID: 27484095
[TBL] [Abstract][Full Text] [Related]
17. Extracting Pathway-level Signatures from Proteogenomic Data in Breast Cancer Using Independent Component Analysis.
Liu W; Payne SH; Ma S; Fenyö D
Mol Cell Proteomics; 2019 Aug; 18(8 suppl 1):S169-S182. PubMed ID: 31213479
[TBL] [Abstract][Full Text] [Related]
18. Proteogenomic Analysis of Human Colon Cancer Reveals New Therapeutic Opportunities.
Vasaikar S; Huang C; Wang X; Petyuk VA; Savage SR; Wen B; Dou Y; Zhang Y; Shi Z; Arshad OA; Gritsenko MA; Zimmerman LJ; McDermott JE; Clauss TR; Moore RJ; Zhao R; Monroe ME; Wang YT; Chambers MC; Slebos RJC; Lau KS; Mo Q; Ding L; Ellis M; Thiagarajan M; Kinsinger CR; Rodriguez H; Smith RD; Rodland KD; Liebler DC; Liu T; Zhang B;
Cell; 2019 May; 177(4):1035-1049.e19. PubMed ID: 31031003
[TBL] [Abstract][Full Text] [Related]
19. Proteogenomic Workflow Reveals Molecular Phenotypes Related to Breast Cancer Mammographic Appearance.
De Marchi T; Pyl PT; Sjöström M; Klasson S; Sartor H; Tran L; Pekar G; Malmström J; Malmström L; Niméus E
J Proteome Res; 2021 May; 20(5):2983-3001. PubMed ID: 33855848
[TBL] [Abstract][Full Text] [Related]
20. Establishment of patient-derived gastric cancer xenografts: a useful tool for preclinical evaluation of targeted therapies involving alterations in HER-2, MET and FGFR2 signaling pathways.
Wang H; Lu J; Tang J; Chen S; He K; Jiang X; Jiang W; Teng L
BMC Cancer; 2017 Mar; 17(1):191. PubMed ID: 28292264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
